EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cancer survivorship in malignant melanoma

Markus Reitmajer iD, Susanne Dugas-Breit iD, Chiara L Blomen iD, Elisabeth Livingstone, Max Schlaak, Markus V Heppt, Michael M Sachse, Madlen Hörold, Friedegund Meier, Sebastian Haferkamp, Christian Apfelbacher iD, Georgia Schilling und 4 weitere

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026

DOI: 10.1111/ddg.70486x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2026. Verfasst von Markus Reitmajer und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Immune Checkpoint Inhibitors, Survivorship. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Robust long‐term survival data have transformed the prognosis of metastatic melanoma. For combination therapy with immune checkpoint inhibitors (ICIs), 10‐year melanoma‐specific survival rates now exceed 50 %, and durable disease control is achievable in a substantial proportion of patients, including those with brain metastases. With increasing long‐term survival, chronic and late‐onset treatment‐related toxicities are becoming increasingly relevant. In particular, chronic immune‐related adverse events (irAEs) may persist after discontinuation of ICI therapy or emerge with delayed onset. These toxicities can significantly impair long‐term quality of life and often require ongoing management; endocrine toxicities, for example, may necessitate lifelong hormone replacement therapy. In addition to physical sequelae, survivors frequently experience psychosocial and financial burdens, difficulties returning to work, and concerns related to fertility and family planning. These multidimensional challenges highlight the growing importance of survivorship care in patients treated with ICIs. Systematic assessment of physical and psychosocial burden as well as health‐related quality of life, especially through patient‐reported outcomes, can support clinical decision‐making and individualized follow‐up strategies. Integrating these assessments into structured, multidisciplinary survivorship care models is essential to address the complex long‐term needs of melanoma survivors and to optimize outcomes beyond disease control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsImmune Checkpoint InhibitorsSurvivorshipCancer SurvivorsHumansQuality of Life

Stichwörter der Autor:innen

follow‐uphealth‐related quality of life (HRQoL)immune checkpoint inhibitor (ICI)immune‐related adverse events (irAEs)melanomaquality of life (QoL)surveillancesurvivorship

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.
  • Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Ge…
  • Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.

ORCID-Profile: Markus Reitmajer, Susanne Dugas-Breit, Chiara L Blomen, Christian Apfelbacher, Frank Meiss, Andrea Forschner

Zitieren

APA

Reitmajer, M., Dugas-Breit, S., Blomen, C. L., Livingstone, E., Schlaak, M., Heppt, M. V., Sachse, M. M., Hörold, M., Meier, F., Haferkamp, S., Apfelbacher, C., Schilling, G., von den Berg, A., Meiss, F., Zimmer, L., & Forschner, A. (2026). Cancer survivorship in malignant melanoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.70486x

Vancouver

Reitmajer M, Dugas-Breit S, Blomen CL, Livingstone E, Schlaak M, Heppt MV, et al. Cancer survivorship in malignant melanoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.70486x

BibTeX
@article{Reitmajer2026,
  author = {Reitmajer, Markus and Dugas-Breit, Susanne and Blomen, Chiara L and Livingstone, Elisabeth and Schlaak, Max and Heppt, Markus V and Sachse, Michael M and Hörold, Madlen and Meier, Friedegund and Haferkamp, Sebastian and Apfelbacher, Christian and Schilling, Georgia and von den Berg, Andrea and Meiss, Frank and Zimmer, Lisa and Forschner, Andrea},
  title = {Cancer survivorship in malignant melanoma},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2026},
  doi = {10.1111/ddg.70486x}
}
Kostenlos starten →